Home
Scholarly Works
Secukinumab provides greater 52-week sustained...
Conference

Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab

Authors

Blauvelt A; Mehlis S; Vanaclocha F; Vender R; Zhao Y; Gilloteau I; Williams N; Guana A; Tyring S

Volume

76

Pagination

pp. AB230-AB230

Publisher

MOSBY-ELSEVIER

Publication Date

June 1, 2017

Name of conference

Annual Meeting of the American-Academy-of-Dermatology

Conference place

Orlando, FL

Conference start date

March 3, 2017

Conference end date

March 7, 2017

Conference proceedings

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Issue

6

ISSN

0190-9622

Labels

Fields of Research (FoR)

Contact the Experts team